肝移植（LT）为肝细胞癌（HCC）患者提供了最好的治愈机会，因为它同时解决了基础疾病和肿瘤。三十多年来，米兰标准一直是选择可从 LT 受益的 HCC 患者的标准。虽然早期研究显示活体供体 LT (LDLT) 后 HCC 复发率较高，但最近的系列研究，尤其是过去十年的研究表明，与已故供体 LT (DDLT) 治疗 HCC 相比，LDLT 具有相同的肿瘤学结果，即使是在以下患者中：米兰标准。此外，处理分析数据的目的表明 LDLT 实际上可能提供生存优势。在西方，与 DDLT 同等的改善结果、LT 计时能力等因素导致针对该适应症进行 LDLT 的数量稳步增加。另一方面，在东方，鉴于其地缘社会文化特质，LDLT 一直是 HCC LT 的主要形式，因此导致世界各地针对该适应症进行的 LDLT 数量不断增加。虽然与 DDLT 相比，HCC 中的 LDLT 具有独特的优势，但在选择 LDLT 患者时，必须考虑平衡供者风险与受者结果的双重平衡。已经取得了一些进展，包括降期疗法的应用和生物标志物的使用，这进一步有助于改善该适应症的 LDLT 的结果。本综述旨在提供与 HCC LDLT 实践相关的移植肿瘤学领域的最新进展。© 2024 印度国家肝脏研究协会。由 Elsevier B.V. 出版。保留所有权利，包括文本和数据挖掘、人工智能培训和类似技术的权利。

Liver transplantation (LT) offers the best chance of cure for patients with hepatocellular carcinoma (HCC), as it addresses simultaneously the underlying disease and the tumour. The Milan criteria has been the standard for over 3 decades in selecting patients with HCC who will benefit from LT. While, early studies showed higher recurrence rates for HCC following living donor LT (LDLT), recent series, especially in the past decade have shown LDLT to have equal oncological outcomes as compared to deceased donor LT (DDLT) for HCC, even in patients beyond Milan criteria. Further, the intention to treat analysis data suggests that LDLT may actually provide a survival advantage. In the west, factors such as improved outcomes on par with DDLT, ability to time the LT etc., have led to a steadily increased number of LDLTs being performed for this indication. On the other hand, in the east, given its geo-socio-cultural idiosyncrasies, LDLT has always been the predominant form of LT for HCC, consequently resulting in an increased number of LDLTs being performed for this indication across the world. While LDLT in HCC has its distinctive advantages compared to DDLT, the double equipoise of balancing the donor risk with the recipient outcomes has to be considered while selecting patients for LDLT. There have been several advances including the application of downstaging therapies and the use of biological markers, which have further helped improve outcomes of LDLT for this indication. This review aims to provide an update on the current advances in the field of transplant oncology related to the practice of LDLT in HCC.© 2024 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.